Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Item
http://www.wikidata.org/entity/Q34227492
Representative Sinusoids for Hepatic Four-Scale Pharmacokinetics SimulationsTranslational learning from clinical studies predicts drug pharmacokinetics across patient populations.The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescentsProximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substratesSemiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.CYP3A activity: towards dose adaptation to the individual.Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol.Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?Optimizing care for the obese patient in interventional radiologyRisk factor analysis of additional administration of sedative agent and patient dissatisfaction in intravenous conscious sedation using midazolam for third molar extraction.Hypertension in Obesity and the Impact of Weight Loss.A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).High-Fat Diet Feeding Alters Expression of Hepatic Drug-Metabolizing Enzymes in Mice.Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
P2860

Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Item
http://www.wikidata.org/entity/Q34227492
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@ast
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@en
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@nl
type
label
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@ast
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@en
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@nl
prefLabel
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@ast
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@en
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Midazolam pharmacokinetics in ...... rison with healthy volunteers.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P6179
P698
P921
P932